The importance of the cytochrome P450 2C9 genotyping on the bleeding complications of patients taking acenocoumarol;A citokróm P450 2C9 genotípus jelentosége acenocoumarollal kezelt betegek vérzéses szövodmé nyeire

Orvosi Hetilap

Volumn 146, Issue 16, 2005, Pages 739-743

  Márk, László ^a,c   Márki Zay, János ^b   Fodor, Lajos ^b   Kondacs, András ^c   Paragh, György ^d   Katona, András ^a  

^a Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza   (Hungary)

^b Kútvölgyi Klinikai Tömb   (Hungary)

^c Számítástechnikai Osztály ^*  (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Acenocoumarol; Bleeding complications; Cytochrome P 450 2C9; Oral anticoagulants; Pharmacogenetics

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; BLEEDING; COMORBIDITY; CONTROLLED STUDY; DIET; DRUG DOSE REGIMEN; DRUG USE; ENZYME POLYMORPHISM; FEMALE; FREQUENCY ANALYSIS; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; REVIEW; THROMBOEMBOLISM; ARTICLE; CHEMICALLY INDUCED DISORDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK;

ACENOCOUMAROL; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 21744456734     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Aithal, G. P., Cay, C. P., Kesteven, P. J. L. és mtsa: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353, 717-719.
2. Blaskó Gy.: Az atherothrombosis gyógyszeres kezelésének alapelvei. In Az atherothrombosis. A patofiziológiai alapoktól a prevencióig. Szerk.: Blaskó Gy. Pharma Press, Budapest, 2003. 103-111. old.
3. Corsini, A., Bellosta S., Baeta, R. és mtsai: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and therapeutics, 1999, 84, 413-428.
4. Daly, A. K., King, B. P.: Pharmacogenetics of oral anticoagulants. Pharmacogenetics, 2003, 13, 247-52.
5. Hermida, J., Zarza, J., Alberca, I. és mtsai: Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood, 2002, 99, 4237-4239.
6. Higashi, M. K., Veenstra, D. L., Kondo, L. M. és mtsai: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA, 2002, 287, 1690-1698.
7. Katona A., Márk L.: Az orális antikoaguláns kezelés gyakorlatának retrospektív elemzése kardiovaszkuláris betegségben szenvedõ betegekben. Orv. Hetil., 2004, 145, 1643-1648.
8. Laporte, S., Quenet, S., Buchmuller-Cordier, A. és mtsai: Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb. Haemost., 2003, 89, 458-467.
9. van der Meer, F., Rosendaal, F., Vandenbroucke, J. és mtsa: Bleeding complications in oral anticoagulant therapy. Arch. Intern. Med., 1993, 153, 1557.
10. Miners, J. O., Birkett, D. J.: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 1998, 45, 525-538.
11. Morin, S., Bodin, L., Loriot M-A. és mtsai: Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther., 2004, 75, 403-414.
12. Palareti, G., Leali, N., Coccheri S és mtsai on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, 1996, 348, 423.
13. Panneerselvam, S., Baglin, C., Lefort, W. és mtsa: Analysis of risk factors for over anticoagulation in patients receiving long-term warfarin. B. J. Haematol., 1998, 103, 422.
14. Sas G.: Hemostaseológia (gyakorló orvosoknak). Melania, Budapest, 2001. 208-215. old.
15. Sas G.: A warfarin hazai bevezetésérõl. Gyógyszereink, 2003, 53, 3-8.
16. Schalekamp, T., van Geest-Daalderop, J. H. H., de Vries-Goldschmeding, H. és mtsai: Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clin. Pharmacol. Ther., 2004, 75, 394-402.
17. Takahashi, H., Wilkinson, G. R., Padrini, R. és mtsa: CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin. Pharmacol. Ther., 2004, 75, 376-380.
18. Taube, J., Halsall, D., Baglin, T.: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96, 1816-1819.
19. Tanaka, E.: Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther., 1999, 24, 339-346.
20. Tassies, D., Freire, C, Pijoan, J. és mstai: Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica, 2002, 87, 1185-1191.
21. Thijssen, H. H., Rìtzen, B.: Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. Ther., 2003, 74, 61-68.
22. Verstuyft, C., Marin, S., Robert, A. és mtsai: Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics, 2001, 11, 735-737.
23. Verstuyft, C., Robert, A., Morin, S. és mtsai: Genetic and environmental risk factors for oral anticoagulant overdose. Eur. J. Clin. Pharmacol., 2003, 58, 739-745.
24. Visser, L. E., van Vliet, M., van Schaik, R. H. és mtsai: The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 2004, 14, 27-33.
25. Visser, L. E., van Schaik, R. H., van Vliet, M. és mtsai: The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost., 2004, 92, 61-66.